C3 glomerulopathies: dense deposit disease and C3 glomerulonephritis [PDF]
Frontiers in Medicine, 2023 Dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) are types of membranoproliferative glomerulonephritis classified as C3 glomerulopathies.
Claudio Ponticelli +4 more
doaj +4 more sources
C3-glomerulonephritis in New Zealand – a case series [PDF]
BMC Nephrology, 2020 Background C3-glomerulonephritis can lead to progressive renal impairment from complement-mediated glomerular injury. Incidence and outcomes of C3-glomerulonephritis are not known in the New Zealand population.
Luke J. Sutherland, Hari Talreja
doaj +7 more sources
Diverse Clinical Presentations of C3 Dominant Glomerulonephritis [PDF]
Frontiers in Medicine, 2020 C3 dominant immunofluorescence staining is present in a subset of patients with idiopathic immune complex membranoproliferative glomerulonephritis (iMPGN).
Ramy M. Hanna +13 more
doaj +5 more sources
C3 Glomerulonephritis Post COVID-19 Vaccination: A Case Report and Review of the Literature [PDF]
Brown Journal of Hospital Medicine, 2022 COVID-19 vaccines are safe and effective at preventing severe illness of COVID -19. There are increasing reports of glomerulonephritis post COVID-19 vaccination.
Arjun Sekar +2 more
doaj +2 more sources
The impact of reclassification of C3 predominant glomerulopathies on diagnostic accuracy, outcome and prognosis in patients with C3 glomerulonephritis [PDF]
BMC Nephrology, 2020 Background C3 glomerulonephritis is a recently described entity with heterogeneous histopathological features. This study was conducted to assess the effect of reclassification of C3 glomerulopathies on renal outcomes, mortality, and response to therapy.
P. Puri +5 more
doaj +2 more sources
C3 Glomerulonephritis Associated with Monoclonal Gammopathy. [PDF]
Indian J NephrolC3 glomerulonephritis (C3GN) is rare. It is a proliferative glomerulonephritis resulting from glomerular deposition of complement factors due to dysregulation of the alternative pathway of complement. The association between monoclonal protein production and development of C3GN was described.
Piedade AD +4 more
europepmc +3 more sources
C3 Glomerulonephritis: A Rare Etiology of the Pulmonary Renal Syndrome [PDF]
Kidney Medicine, 2019 C3 Glomerulopathy is a rare form of kidney disease due to dysregulation of the alternative complement pathway. We report a case of a college-aged woman with C3 glomerulonephritis (C3GN), presenting with the unexpected extrarenal manifestation of ...
Shane A. Bobart +2 more
doaj +2 more sources
Timing of eculizumab therapy for C3 glomerulonephritis. [PDF]
Clin Kidney J, 2015 Eculizumab is an anti-C5 antibody that inhibits C5 cleavage and prevents the generation of the terminal complement complex C5b-9. Eculizumab is licensed to treat paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome (aHUS). Clinical trials are ongoing for C3 glomerulopathy.
Rodriguez-Osorio L, Ortiz A.
europepmc +3 more sources
C3 glomerulonephritis accompanied with lupus nephritis
Nefrología (English Edition), 2021 Kubra Kaynar +4 more
doaj +5 more sources
Cat-Scratch Disease Masquerading as C3 Glomerulonephritis. [PDF]
Kidney Int Rep, 2020 Sutu B +6 more
europepmc +5 more sources